Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study
about
Cervical lymph node diseases in childrenLucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjectsEffect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trialTreatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy.Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database.Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patientsEnzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.Gaucher disease: Progress and ongoing challenges.Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease
P2860
Q26865114-11BC9EB5-7895-4F44-93CD-0E56936E3936Q28468569-06C0B6D3-AF87-4341-88CA-6EB9DF0FEF95Q33420506-062AA985-080D-452C-B983-C44D7199254BQ33435875-D07F5E94-0A52-41DA-9FAC-3878CA7ACC93Q33443605-1275F108-A7DB-431C-B8CB-D7F34F019905Q33615625-4B0AF781-8F30-4A83-8807-1D8D26582EDFQ35806919-B73F5315-0269-47FD-85F0-78A56E4A82D1Q35868559-A994F569-D702-4F51-B4AE-5AD50B347341Q36725221-4D52962F-E9C9-458B-9925-B9E44B76A2EDQ37167690-F8F26CAA-5AFE-46EE-A674-1F8DA318CCF0Q37400927-A1697C66-4B18-407D-B7A3-72984D5CE879Q39028972-FBD834DF-3388-4694-A1A4-017A86975FE7Q47548732-D6084E88-F103-4E51-B66E-285D3CB72F3FQ57159147-F5E36A39-D3AE-43DC-8E24-80E0CED80EA7
P2860
Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Evaluation of miglustat as mai ...... en-label non-inferiority study
@ast
Evaluation of miglustat as mai ...... en-label non-inferiority study
@en
type
label
Evaluation of miglustat as mai ...... en-label non-inferiority study
@ast
Evaluation of miglustat as mai ...... en-label non-inferiority study
@en
prefLabel
Evaluation of miglustat as mai ...... en-label non-inferiority study
@ast
Evaluation of miglustat as mai ...... en-label non-inferiority study
@en
P2093
P2860
P356
P1476
Evaluation of miglustat as mai ...... en-label non-inferiority study
@en
P2093
Carla Em Hollak
Cecile Luzy
Dominick Amato
Mariabeth Silkey
Miglustat Maintenance Study Group
Robert D Steiner
Ruben Giorgino
Timothy M Cox
P2860
P2888
P356
10.1186/1750-1172-7-102
P577
2012-12-27T00:00:00Z
P5875
P6179
1022939752